FDA Alert: ' Substantial ' Hypocalcemia Risk with Prolia Use FDA Alert: ' Substantial ' Hypocalcemia Risk with Prolia Use

The US Food and Drug Administration sent an alert today that it ' s investigating an apparent link between the use of denosumab (Prolia) by patients on dialysis and serious hypocalcemia outcomes.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Nephrology News Alert Source Type: news